865156-71-4

Basic information

• Product Name: 5-broMo-2-Methoxy-3-(3-Methoxypropoxy)pyridine
• Synonyms: 5-broMo-2-Methoxy-3-(3-Methoxypropoxy)pyridine
• CAS NO: 865156-71-4
• Molecular Formula: C₁₀H₁₄BrNO₃
• Molecular Weight: 276
• Mol File: 865156-71-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMo-2-Methoxy-3-(3-Methoxypropoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-2-Methoxy-3-(3-Methoxypropoxy)pyridine(865156-71-4)
• EPA Substance Registry System: 5-broMo-2-Methoxy-3-(3-Methoxypropoxy)pyridine(865156-71-4)

Safety Data

• Hazardous Substances Data: 865156-71-4(Hazardous Substances Data)

Upstream product

• 865156-72-5 5-bromo-3-(3-methoxy-propoxy)-1H-pyridin-2-one 
• 74-88-4 methyl iodide 
• 286946-77-8 5-bromo-2-chloro-3-hydroxypyridine 
• 124-41-4 sodium methylate 
• 74115-13-2 5-bromopyridine-3-ol 
• 67-56-1 methanol 

Relevant articles and documents

METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS

The invention relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.

SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME

The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.

5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION

The application relatés to novel alkanamides of the general formula (I) where X is -CH2- or >CH-OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl-C1-C6-alkyl; R5 is Cl-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy- C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-Cl-C6-alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1,-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-Cl-C6-alkyl, optionally substituted aryl--Co-C6-alkyl, optionally substituted C3-C8-cycloalkyl-Co-C6-alkyl or optionally substituted heterocydyl-Co-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.